SG11201909334TA - Proteins for the treatment of epithelial barrier function disorders - Google Patents
Proteins for the treatment of epithelial barrier function disordersInfo
- Publication number
- SG11201909334TA SG11201909334TA SG11201909334TA SG11201909334TA SG 11201909334T A SG11201909334T A SG 11201909334TA SG 11201909334T A SG11201909334T A SG 11201909334TA SG 11201909334T A SG11201909334T A SG 11201909334TA
- Authority
- SG
- Singapore
- Prior art keywords
- avenue
- allerton
- genome
- san francisco
- california
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 230000004890 epithelial barrier function Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 241000234282 Allium Species 0.000 abstract 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 abstract 1
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 abstract 1
- 235000003332 Ilex aquifolium Nutrition 0.000 abstract 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 abstract 1
- 235000002294 Ilex volkensiana Nutrition 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 230000004888 barrier function Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000002919 epithelial cell Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Prostheses (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482963P | 2017-04-07 | 2017-04-07 | |
| US201762607706P | 2017-12-19 | 2017-12-19 | |
| US201762611334P | 2017-12-28 | 2017-12-28 | |
| PCT/US2018/026447 WO2018187682A1 (en) | 2017-04-07 | 2018-04-06 | Proteins for the treatment of epithelial barrier function disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909334TA true SG11201909334TA (en) | 2019-11-28 |
Family
ID=63710147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909334T SG11201909334TA (en) | 2017-04-07 | 2018-04-06 | Proteins for the treatment of epithelial barrier function disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10251933B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3606542A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7789303B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200003821A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110769844B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018248324B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3059354A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL269853A (cg-RX-API-DMAC7.html) |
| MX (2) | MX393998B (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201909334TA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI797116B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018187682A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10251933B2 (en) | 2017-04-07 | 2019-04-09 | Second Genome, Inc. | Proteins for the treatment of epithelial barrier function disorders |
| US11666627B2 (en) | 2017-04-07 | 2023-06-06 | Second Genome, Inc. | Proteins for the treatment of epithelial barrier function disorders |
| EP3773644A4 (en) * | 2018-04-06 | 2021-06-02 | Second Genome, Inc. | Proteins for the treatment of epithelial barrier function disorders |
| JP2022512639A (ja) * | 2018-10-09 | 2022-02-07 | セカンド ゲノム インコーポレイテッド | 上皮バリア機能障害の治療に有効なタンパク質を送達するためのラクトコッカス・ラクティス発現系 |
| WO2021035129A1 (en) * | 2019-08-21 | 2021-02-25 | Astrazeneca Collaboration Ventures, Llc | Use of brazikumab to treat crohn's disease |
| US11666629B2 (en) * | 2020-01-10 | 2023-06-06 | National Taipei University Of Technology | Peptide interacting with toll-like receptor 2 and the composition comprising the same |
| CN113773364B (zh) * | 2021-08-25 | 2023-04-28 | 无锡市儿童医院 | 小分子肽及其制备方法和应用 |
| WO2024098026A2 (en) * | 2022-11-04 | 2024-05-10 | Mink Therapeutics, Inc. | B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5783415A (en) | 1991-03-29 | 1998-07-21 | Genentech, Inc. | Method of producing an IL-8 receptor polypeptide |
| AR053579A1 (es) * | 2005-04-15 | 2007-05-09 | Genentech Inc | Tratamiento de la enfermedad inflamatoria intestinal (eii) |
| ES2568938T3 (es) | 2009-04-28 | 2016-05-05 | Vanderbilt University | Composiciones y procedimientos de tratamiento de trastornos que implican apoptosis de células epiteliales |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| JP2014093482A (ja) | 2012-11-06 | 2014-05-19 | Toshiba Corp | 固体撮像装置の製造方法および固体撮像装置 |
| GB201306536D0 (en) * | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| WO2015014973A2 (en) * | 2013-07-31 | 2015-02-05 | Institut National De La Recherche Agronomique | Use of specific glycoside phosphorylases for the implementation of phosphorolysis or reverse phosphorolysis reactions |
| PT3307288T (pt) * | 2015-06-15 | 2019-10-17 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
| US10251933B2 (en) | 2017-04-07 | 2019-04-09 | Second Genome, Inc. | Proteins for the treatment of epithelial barrier function disorders |
| US11666627B2 (en) * | 2017-04-07 | 2023-06-06 | Second Genome, Inc. | Proteins for the treatment of epithelial barrier function disorders |
| WO2018223051A1 (en) | 2017-06-02 | 2018-12-06 | Second Genome, Inc. | Proteins for the treatment of epithelial barrier function disorders |
-
2018
- 2018-04-06 US US15/947,263 patent/US10251933B2/en active Active
- 2018-04-06 CA CA3059354A patent/CA3059354A1/en active Pending
- 2018-04-06 EP EP18781398.5A patent/EP3606542A4/en active Pending
- 2018-04-06 AU AU2018248324A patent/AU2018248324B2/en active Active
- 2018-04-06 KR KR1020197032830A patent/KR20200003821A/ko not_active Ceased
- 2018-04-06 CN CN201880037987.0A patent/CN110769844B/zh active Active
- 2018-04-06 SG SG11201909334T patent/SG11201909334TA/en unknown
- 2018-04-06 MX MX2019012051A patent/MX393998B/es unknown
- 2018-04-06 WO PCT/US2018/026447 patent/WO2018187682A1/en not_active Ceased
- 2018-04-06 JP JP2019554976A patent/JP7789303B2/ja active Active
- 2018-04-06 US US16/603,507 patent/US11207376B2/en active Active
- 2018-04-09 TW TW107112165A patent/TWI797116B/zh active
-
2019
- 2019-10-06 IL IL26985319A patent/IL269853A/en unknown
- 2019-10-07 MX MX2022008842A patent/MX2022008842A/es unknown
-
2023
- 2023-04-24 US US18/305,899 patent/US20240066095A1/en active Pending
- 2023-05-08 AU AU2023202844A patent/AU2023202844A1/en not_active Abandoned
- 2023-12-11 JP JP2023208379A patent/JP2024037834A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20180289770A1 (en) | 2018-10-11 |
| US20200148728A1 (en) | 2020-05-14 |
| AU2018248324A1 (en) | 2019-10-31 |
| MX2019012051A (es) | 2020-02-12 |
| CN110769844A (zh) | 2020-02-07 |
| WO2018187682A1 (en) | 2018-10-11 |
| AU2018248324B2 (en) | 2023-02-09 |
| MX2022008842A (es) | 2022-08-02 |
| TW201841649A (zh) | 2018-12-01 |
| JP2020516615A (ja) | 2020-06-11 |
| US20240066095A1 (en) | 2024-02-29 |
| EP3606542A1 (en) | 2020-02-12 |
| US10251933B2 (en) | 2019-04-09 |
| US11207376B2 (en) | 2021-12-28 |
| IL269853A (en) | 2019-11-28 |
| EP3606542A4 (en) | 2021-01-20 |
| JP2024037834A (ja) | 2024-03-19 |
| MX393998B (es) | 2025-03-24 |
| JP7789303B2 (ja) | 2025-12-22 |
| TWI797116B (zh) | 2023-04-01 |
| CN110769844B (zh) | 2025-01-21 |
| KR20230144097A (ko) | 2023-10-13 |
| AU2023202844A1 (en) | 2023-07-06 |
| CA3059354A1 (en) | 2018-10-11 |
| KR20200003821A (ko) | 2020-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909334TA (en) | Proteins for the treatment of epithelial barrier function disorders | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| SG11201811151PA (en) | Extracellular vesicle comprising a fusion protein having fc binding capacity | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201908650PA (en) | Optimized antibody compositions for treatment of ocular disorders | |
| SG11201806845VA (en) | Moisturizing compositions and uses thereof | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201811549UA (en) | Boronic acid derivatives and therapeutic uses thereof | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201811209QA (en) | Oral gastroretentive formulations and uses thereof | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof |